Form 4: Jasper Therapeutics CEO Ron Martell Granted Stock Options and Performance-Based Restricted Stock Units

Ron Martell, CEO of Jasper Therapeutics, received stock options and performance-based restricted stock units, as detailed in a recent SEC filing.

Summary

• Ron Martell, the President, CEO, and Director of Jasper Therapeutics, Inc., was granted stock options and performance-based restricted stock units (PRSUs) on June 10, 2024.
• The stock options allow Martell to purchase 10,000 shares of voting common stock at an exercise price of $23.95 per share, vesting over four years.
• He also received 20,000 PRSUs, each representing a contingent right to receive one share of common stock.
• If Jasper Therapeutics' common stock price reaches $35.00 or higher for thirty consecutive calendar days by June 10, 2026, all PRSUs will vest, provided Martell remains continuously employed by the company.
• Martell has also granted Herb Cross power of attorney to execute and file SEC forms on his behalf.

Sentiment

Score: 7

Explanation: The document is neutral in tone, detailing standard executive compensation. The performance-based component suggests a positive outlook for the company's future stock performance.

Positives

• The grant of stock options and PRSUs aligns Martell's interests with those of the shareholders, incentivizing him to increase the company's stock value.
• The vesting conditions for the PRSUs, requiring a stock price of $35.00 for 30 consecutive days, set a clear performance target for Martell.

Risks

• The vesting of the PRSUs is contingent on the company's stock price reaching $35.00 by June 10, 2026, which may not occur.
• If Martell leaves the company before the vesting conditions are met, he will forfeit the unvested stock options and PRSUs.

Future Outlook

The vesting of the PRSUs is contingent on the company's stock price performance, indicating a focus on increasing shareholder value.

Industry Context

Granting stock options and PRSUs to executives is a common practice in the biotechnology industry to align management's interests with those of shareholders and incentivize performance.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often used to attract and retain talent.
• Performance-based restricted stock units (PRSUs) are also common, with vesting conditions tied to specific milestones such as clinical trial results, regulatory approvals, or stock price targets.
• Comparable companies like Sangamo Therapeutics and CRISPR Therapeutics also utilize stock options and PRSUs in their executive compensation plans.

Stakeholder Impact

• Shareholders may view the grant of stock options and PRSUs positively, as it aligns management's interests with increasing shareholder value.
• Employees may be motivated by the potential for the company's stock price to increase, leading to the vesting of the PRSUs.

Key Dates